Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis

This study is a single-center, open-label, single-arm, exploratory clinical study to evaluate the safety, tolerability, and preliminary efficacy of S103（BCMA-CAR T ）cells in the treatment of progressive or refractory multiple sclerosis. The study is a dose escalation trial in adult progressive and refractory MS patients. A standard "3+3" design will be used to perform dose escalation to explore the safety profile and dose-limiting toxicities (DLTs). A total of 9 MS patients who meet the inclusion criteria are expected to be recruited.

NCT Number	NCT07587125
Lead Sponsor	Xijing Hospital Collaborators: Hebei Senlang Biotechnology Co., LTD
Conditions	Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis, Multiple Sclerosis (MS) Secondary Progressive, Refractory Multiple Sclerosis
Enrollment	9 participants
Start Date	2026-05-08
Primary Completion	2027-11 (estimated)
Study Completion	2029-11 (estimated)
Updated on ClinicalTrials.gov	2026-08-05